MEDDDICAL has announced an advisory service tackling one of pharma's costliest blind spots: committing resources before the right data strategy is defined. Independent guidance across claims data, synthetic cohorts, and AI-powered analytics puts evidence decisions on firmer ground from the start.
-- MEDDDICAL has launched a real-world evidence analytics and advisory service, offering structured guidance to pharmaceutical and MedTech companies at a time when real-world evidence requirements from regulators and payers are growing more demanding across global drug development programs.
More information is available at https://medddical.com/
According to a 2024 IQVIA report, the volume of available real-world health data has grown considerably, yet many pharmaceutical organizations still face challenges in turning that data into evidence that can stand up to regulatory or payer scrutiny. The central issue is rarely a lack of data; more often, it is the difficulty of determining which sources, analytical frameworks, and compliance structures fit a program’s requirements before significant resources are committed.
That is the gap MEDDDICAL aims to address. The team provides independent advisory support across insurance claims data strategy, synthetic patient cohort design, AI-powered analytics guidance, and market access strategy consulting. Operating outside the vendor ecosystem, its recommendations are shaped by client needs rather than provider incentives.
A MEDDDICAL spokesperson said that many organizations begin evaluating vendors before clearly defining the underlying requirements of their program, including the level of data coverage, analytical methodology, and compliance structure needed. “That sequencing problem is where timelines collapse, and budgets get misallocated,” the spokesperson said. “Defining requirements first means every subsequent data decision rests on a clear foundation rather than assumptions.”
This approach becomes especially important in areas such as HEOR evidence development, loss-of-exclusivity forecasting, patient journey analysis, and AI-driven commercial sizing, where alignment between a program’s needs and a vendor’s actual capabilities can significantly affect timelines, budget efficiency, and decision quality, the team explains.
Most teams know they need European claims data, multi-country RWE, or GDPR-compliant data partnerships — but determining which combination of data sources, providers, and study designs actually fit their strategic objectives requires a level of market knowledge that internal teams rarely have bandwidth to build. MEDDDICAL operates as a neutral advisory layer between qualified organisations and health insurance data access partners across Europe and globally — handling the strategic evaluation, compliance navigation, and use-case alignment so that evidence teams can move faster and smarter, without over-committing to the wrong data relationship.
About MEDDDICAL
MEDDDICAL, which was founded on the belief that clearer evidence-based decisions lead to better patient outcomes, provides pharmaceutical and MedTech organizations with independent guidance in a data environment where poor choices can result in lost time and missed opportunities.
Further company information is available at https://medddical.com/
Contact Info:
Name: Rainer Muller
Email: Send Email
Organization: MeDDDical
Address: Aptos 221 Edificio D2C, Sotogrande, Cadiz 11310, Spain
Website: https://medddical.com
Source: NewsNetwork
Release ID: 89188753
If there are any deficiencies, discrepancies, or concerns regarding the information presented in this press release, we kindly request that you promptly inform us by contacting error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our dedicated team is committed to addressing any identified issues within 8 hours to guarantee the delivery of accurate and reliable content to our esteemed readers.
